Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dexamethasone

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44339   clinical trials with a EudraCT protocol, of which   7369   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    847 result(s) found for: Dexamethasone. Displaying page 9 of 43.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    EudraCT Number: 2012-003661-17 Sponsor Protocol Number: SS01 Start Date*: 2012-11-09
    Sponsor Name:Moorfields Eye Hospital NHS Foundation Trust
    Full Title: A Multicentre Prospective Open-label Randomised Clinical Trial Comparing the Efficacy of Fixed versus PRN dosing of 700 µg Dexamethasone Posterior Segment Drug Delivery System (DEX PS DDS) in patie...
    Medical condition: Diabetic macular oedema
    Disease: Version SOC Term Classification Code Term Level
    14.1 10015919 - Eye disorders 10057915 Diabetic macular oedema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-003815-46 Sponsor Protocol Number: 37826 Start Date*: 2012-05-15
    Sponsor Name:Erasmus MC
    Full Title: Double blind placebo controlled randomized intervention study aiming at reducing dexamethasone related side effects in children with acute lymphoblastic leukemia (ALL).
    Medical condition: Acute lymphoblastic leukemia
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10001690 ALL LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001443-31 Sponsor Protocol Number: RC12_0447 Start Date*: 2013-12-30
    Sponsor Name:CHU de Nantes
    Full Title: Phase II trial studying the efficacy of a triplet combination of MLN9708, lenalidomide and dexamethasone as induction prior to, and as consolidation after high-dose therapy with peripheral stem cel...
    Medical condition: Young untreated patients with multiple myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2010-020924-22 Sponsor Protocol Number: RG_09-072 Start Date*: 2011-12-02
    Sponsor Name:University of Birmingham
    Full Title: United Kingdom National Randomised Trial for Children and Young Adults with Acute Lymphoblastic Leukaemia and Lymphoma 2011
    Medical condition: Acute lymphoblastic leukaemia and lymphoblastic lymphoma
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10000845 Acute lymphoblastic leukemia LLT
    18.1 100000004864 10065923 Lymphoblastic lymphoma LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-000781-37 Sponsor Protocol Number: NKV102549 Start Date*: 2006-07-24
    Sponsor Name:GlaxoSmithKline Research and Development Ltd
    Full Title: A Phase III, Multicenter, Randomized, Double-Blind, Active Controlled, Parallel Group Study of the Safety and Efficacy of the Intravenous and Oral Formulations of the Neurokinin-1 Receptor Antagon...
    Medical condition: Chemotherapy induced nausea and vomiting (CINV) due to Moderately Emetogenic Chemotherapy (MEC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) BE (Completed) IE (Completed) SK (Completed) ES (Completed) AT (Completed) EE (Completed) CZ (Completed) LT (Completed) HU (Completed) DK (Completed) LV (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2020-003024-16 Sponsor Protocol Number: ACT16482 Start Date*: 2021-06-30
    Sponsor Name:Sanofi-Aventis Recherche & Developpement
    Full Title: Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents in relapsed or refractory multiple myeloma (RRMM) - Master protocol
    Medical condition: Plasma cell myeloma refractory
    Disease: Version SOC Term Classification Code Term Level
    22.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10081847 Plasma cell myeloma refractory PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NO (Trial now transitioned) FR (Completed) GR (Trial now transitioned) PT (Trial now transitioned) DE (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2018-003287-31 Sponsor Protocol Number: M16-104 Start Date*: 2019-06-05
    Sponsor Name:AbbVie Deutschland GmbH & Co. KG
    Full Title: A Phase 2, Multicenter, Single Arm, Open Label Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are In...
    Medical condition: Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-003092-18 Sponsor Protocol Number: TIKTAC Start Date*: 2021-05-12
    Sponsor Name:Medical University Innsbruck
    Full Title: Daratumumab in combination with Carfilzomib, Pomalidomide and Dexamethasone (DCPD) in patients with multiple myeloma induced acute renal failure - “Time Is Kidney in the Treatment of myelomA Cast n...
    Medical condition: Multiple Myeloma: cohort 1: dialysis dependent patients; cohort 2: patients not dialysis dependent
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-005008-24 Sponsor Protocol Number: GEM-KyCyDex Start Date*: 2017-11-13
    Sponsor Name:FUNDACIÓN PETHEMA
    Full Title: Carfilzomib and Dexamethasone in combination with Cyclophosphamide vs. Carfilzomib and Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma: a phase II randomized controlled trial.
    Medical condition: Relapsed/Refractory Multiple Myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000054086 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-000605-84 Sponsor Protocol Number: XPORT-DLBCL-030 Start Date*: 2020-09-16
    Sponsor Name:Karyopharm Therapeutics Inc.
    Full Title: A Phase 2/3, Multicenter Randomized Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DL...
    Medical condition: Relapsed/Refractory Diffuse Large B-Cell Lymphoma (RR DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    21.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing) FR (Ongoing) IT (Trial now transitioned) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2009-015507-52 Sponsor Protocol Number: CLBH589D2308 Start Date*: 2009-11-13
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, double-blind, placebo controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma
    Medical condition: Multiple Myeloma (MM), relapsed or relapsed-and-refractory
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) FI (Completed) DE (Completed) NL (Completed) BE (Completed) DK (Completed) IT (Completed) FR (Completed) ES (Completed) CZ (Completed) PL (Completed) GB (Completed) AT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2016-002438-58 Sponsor Protocol Number: BAY88-8223/18987 Start Date*: 2016-11-16
    Sponsor Name:Bayer AG
    Full Title: A phase 1b/2 trial to evaluate the safety and efficacy of radium-223 dichloride (BAY 88-8223) in combination with bortezomib and dexamethasone in early relapsed multiple myeloma
    Medical condition: Relapsed multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2010-021295-28 Sponsor Protocol Number: ottavi Start Date*: 2010-09-30
    Sponsor Name:AZIENDA OSPEDALIERA MAGGIORE DELLA CARITA` DI NOVARA
    Full Title: therapy antiedemigena through administration of corticosteroidi after surgical extraction of the teeth of the judgment.
    Medical condition: This study is going to be performed on patients afferent to the service of Chirurgia Maxillo Facciale dell’Ospedale Maggiore della Carita` di Novara subject to eights bony included extraction.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10042613 SOC
    Population Age: In utero, Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001019-30 Sponsor Protocol Number: CRFB002EDE17 Start Date*: 2011-06-01
    Sponsor Name:Novartis Pharma GmbH
    Full Title: A 6-month multicenter, randomized, double-masked phase IIIb-study comparing the efficacy and safety of Lucentis (Ranibizumab) intravitreal injections versus Ozurdex (Dexamethasone) intravitreal imp...
    Medical condition: visual impairment due to macular edema following branch retinal vein occlusion (BRVO)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004853 10054467 Macular edema LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) HU (Completed) CZ (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2013-001093-16 Sponsor Protocol Number: DX203 Start Date*: 2013-07-16
    Sponsor Name:Oculis ehf.
    Full Title: Comparison of non-MMC trabeculectomy and dexamethasone nanoparticles eye drops with MMC trabeculectomy and Maxidex®
    Medical condition: Anti-inflammatory treatment post trabeculectomy
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IS (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-005700-24 Sponsor Protocol Number: SC Start Date*: 2015-08-17
    Sponsor Name:Abteilung für Augenheilkunde, AKH Linz
    Full Title: Aqueous Humor cytokine Levels following intravitreal ranibizumab or dexamethasone therapy in patients with diabetic macular edema
    Medical condition: Diabetic Retinopathy and diabetic macular edema are leading causes for visual loss and blindness in young adults around the world.
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004853 10057934 Diabetic macular edema LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-005216-24 Sponsor Protocol Number: DSHNHL2005-1 Start Date*: 2009-06-09
    Sponsor Name:University of Saarland
    Full Title: 14-daily Oxaliplatin, Gemcitabine, Dexamethasone and Rituximab with subsequent 90-Y-Zevalin-consolidation for the treamtent of aggressive CD-20-positive B-NHL-relapses in patients with inability to...
    Medical condition: Relapse or primary progress of aggressive CD-20-positive-B-NHL
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052314 Lymphatic disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2018-002634-20 Sponsor Protocol Number: NBF_HK_01_2018 Start Date*: 2018-10-23
    Sponsor Name:Anaesthesia Department, Hvidovre Hospital, Capital Region of Denmark
    Full Title: Highdose steroid for total knee arthroplasty - A randomized doubleblindet controlled trial.
    Medical condition: Perioperative management of total knee-arthroplasty because of knee-osteoarthritis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10042613 - Surgical and medical procedures 10023469 Knee arthroplasty PT
    20.1 100000004863 10054711 Postoperative pain LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2021-004917-38 Sponsor Protocol Number: EAE115 Start Date*: 2022-06-28
    Sponsor Name:Hellenic Society of Hematology (EAE)
    Full Title: A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor
    Medical condition: Multiple myeloma patients who received one prior line of therapy containing Lenalidomide and a Proteasome Inhibitor.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2016-001178-13 Sponsor Protocol Number: NMSG#24/15 Start Date*: 2017-02-02
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Phase 2 study of carfilzomib + elotuzumab + dexamethasone for relapsed or progressed multiple myeloma after 1-3 prior treatment lines
    Medical condition: Multiple myeloma patients
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10067095 Multiple myeloma progression LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) SE (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 5  6  7  8  9  10  11  12  13  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Mon Jun 02 12:45:21 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA